10-K/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-K/A

Amendment No.1

 

 

(Mark One)

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2014

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM                      TO                     

Commission File Number 001-36485

 

 

Ardelyx, Inc.

(Exact name of Registrant as specified in its Charter)

 

 

 

Delaware   26-1303944

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

34175 Ardenwood Blvd., Suite 200

Fremont, California

  94555
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (510) 745-1700

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:

 

Name of Each Exchange on Which Registered:

Common Stock, par value $0.0001 per share   The NASDAQ Global Market

Securities registered pursuant to Section 12(g) of the Act: None

 

 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    YES  ¨    NO  x

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    YES  ¨    NO  x

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  x    NO  ¨

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).    YES  x    NO  ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  x

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definition of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   x  (Do not check if a small reporting company)    Small reporting company   ¨

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    YES  ¨    NO  x

The aggregate market value of the Registrant’s common stock held by non-affiliates of the Registrant as of the last business day of the Registrant’s most recently completed second fiscal quarter, June 30, 2014, based on the last reported sales price of the Registrant’s common stock of $15.97 per share was $96,062,968.

The number of shares of Registrant’s Common Stock outstanding as of February 26, 2015 was 18,598,133.

DOCUMENTS INCORPORATED BY REFERENCE:

Portions of the Registrant’s Definitive Proxy Statement for its 2015 Annual Meeting of Stockholders, which will be filed with the Commission within 120 days after the close of the Registrant’s 2014 fiscal year, are incorporated by reference into Part III of this Report.

 

 

 


EXPLANATORY NOTE

This Amendment No. 1 on Form 10-K/A ( “Amendment No. 1”) is being filed to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 (the “Original Filing”), filed with the U.S. Securities and Exchange Commission on March 5, 2015 (the “Original Filing Date”). The sole purpose of this Amendment No. 1 is to correct the previously filed Consent of Ernst & Young LLP (filed as Exhibit 23.1), which inadvertently contained an incorrect date.

Except as described above, no changes have been made to the Original Filing, and this Amendment No. 1 does not modify, amend or update in any way any of the financial or other information contained in the Original Filing. This Amendment No. 1 does not reflect events that may have occurred subsequent to the Original Filing Date.

Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted.

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a) The following documents are filed as part of this report:

 

  1. Financial Statements*

 

  2. Financial Statement Schedules

All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.

 

  3. Exhibits

See the Exhibit Index immediately following the signature page of this report.

 

* Previously filed with our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 5, 2015, which is being amended hereby.

 

2


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused Amendment No. 1 to this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Ardelyx, Inc.
Date: March 11, 2015 By:

/s/ Mark Kaufmann

Mark Kaufmann

Chief Financial Officer

(Principal Financial Officer)

 

3


Exhibit Index

 

         

Incorporated by Reference

Exhibit
Number

  

Exhibit Description

  

Form

  

Date

  

Number

  

Filed
Herewith

3.1    Amended and Restated Certificate of Incorporation.    8-K    6/24/2014    3.1   
3.2    Amended and Restated Bylaws.    8-K    6/24/2014    3.2   
4.1    Reference is made to exhibits 3.1 and 3.2.            
4.2    Form of Common Stock Certificate.    S-1/A    6/18/2014    4.2   
10.1(a)†   

License Agreement, dated as of October 4, 2012, by and among

AstraZeneca AB and Ardelyx, Inc.

   S-1/A    6/5/2014    10.1(a)   
10.1(b)†   

Amendment Number One to License Agreement, dated as of

December 23, 2013, by and between AstraZeneca AB and Ardelyx, Inc.

   S-1/A    6/5/2014    10.1(b)   
10.2†   

License and Option Agreement, dated February 21, 2014, by and between

Sanofi and Ardelyx, Inc.

   S-1/A    6/5/2014    10.2   
10.3   

Amended and Restated Investor’s Rights Agreement dated June 23, 2011,

by and among Ardelyx, Inc. and the investors listed therein.

   S-1    5/19/2014    10.3   
10.4(a)   

Lease, dated August 8, 2008, by and between 34175 Ardenwood Venture,

LLC and Ardelyx, Inc.

   S-1    5/19/2014    10.4(a)   
10.4(b)   

Amendment to Lease, dated December 20, 2012, by and between 34175

Ardenwood Venture, LLC and Ardelyx, Inc.

   S-1    5/19/2014    10.4(b)   
10.4(c)   

Second Amendment to Lease, dated September 5, 2014, by and between

Ardelyx, Inc. and 34175 Ardenwood Venture, LLC.

   8-K    9/9/2014    10.1   
10.5(a)#    Ardelyx, Inc. 2008 Stock Incentive Plan, as amended.    S-1    5/19/2014    10.5(a)   
10.5(b)#   

Form of Stock Option Grant Notice and Stock Option Agreement under the

2008 Stock Incentive Plan, as amended.

   S-1    5/19/2014    10.5(b)   
10.5(c)#    Form of Restricted Stock Purchase Grant Notice and Restricted Stock Purchase Agreement under the 2008 Stock Incentive Plan, as amended.    S-1    5/19/2014    10.5(c)   
10.6(a)#    Ardelyx, Inc. 2014 Equity Incentive Award Plan.    S-8    7/14/2014    99.3   
10.6(b)#   

Form of Stock Option Grant Notice and Stock Option Agreement

under the 2014 Equity Incentive Award Plan.

   S-1/A    6/18/2014    10.6(b)   
10.6(c)#   

Form of Restricted Stock Award Agreement and Restricted Stock

Unit Award Grant Notice under the 2014 Equity Incentive Award Plan.

   S-1/A    6/18/2014    10.6(c)   
10.7#    Form of Indemnification Agreement for directors and officers.    S-1/A    6/9/2014    10.7   
10.8#   

Amended and Restated Executive Employment Agreement, dated

June 6, 2014, by and between Ardelyx, Inc. and Michael Raab.

   S-1/A    6/9/2014    10.8   
10.9#   

Amended and Restated Change in Control Severance Agreement,

dated June 6, 2014, by and between Ardelyx, Inc. and Mark Kaufmann.

   S-1/A    6/9/2014    10.15   

 

4


           

Incorporated by Reference

Exhibit
Number

    

Exhibit Description

  

Form

  

Date

  

Number

  

Filed
Herewith

10.10#      Amended and Restated Change in Control Severance Agreement, dated June 6, 2014, by and between Ardelyx, Inc. and Elizabeth Grammer, Esq.    S-1/A    6/9/2014    10.16   
10.11#      Amended and Restated Change in Control Severance Agreement, dated June 6, 2014, by and between Ardelyx, Inc. and Jeffrey Jacobs, Ph.D.    S-1/A    6/9/2014    10.17   
10.12#      Amended and Restated Change in Control Severance Agreement, dated June 6, 2014, by and between Ardelyx, Inc. and George Jue.    S-1/A    6/9/2014    10.18   
10.13#      Amended and Restated Change in Control Severance Agreement, dated June 6, 2014, by and between Ardelyx, Inc. and David Rosenbaum, Ph.D.    S-1/A    6/9/2014    10.19   
10.14#      Transition and Separation Agreement dated September 4, 2014, by and between Ardelyx, Inc. and Dominique Charmot, Ph.D.    8-K    9/9/2014    10.2   
10.15#      Offer Letter, dated August 11, 2011, by and between Ardelyx, Inc. and Mark Kaufmann.    S-1/A    6/9/2014    10.10   
10.16#      Offer Letter, dated May 21, 2008, by and between Ardelyx, Inc. and George Jue.    S-1/A    6/9/2014    10.11   
10.17#      Offer Letter, dated May 2, 2008, by and between Ardelyx, Inc. and Jeff Jacobs, Ph.D.    S-1/A    6/9/2014    10.12   
10.18#      Offer Letter, dated December 28, 2009, by and between Ardelyx, Inc. and David Rosenbaum, Ph.D.    S-1/A    6/9/2014    10.13   
10.19#      Offer Letter, dated November 21, 2012, by and between Ardelyx, Inc. and Elizabeth Grammer, Esq.    S-1/A    6/9/2014    10.14   
10.20#*      Offer Letter, dated October 15, 2014, by and between Ardelyx, Inc. and Narani Arasaratnam.            
10.21#*      Change in Control Severance Agreement, dated November 26, 2014, by and Between Ardelyx, Inc. and Narani Arasaratnam.            
10.22#*      Offer Letter, dated November 21, 2014, by and between Ardelyx, Inc. and Jeremy S. Caldwell, Ph.D.            
10.23#*      Change in Control Severance Agreement, dated December 19, 2014, by and between Ardelyx, Inc. and Jeremy S. Caldwell, Ph.D.            
10.24#      Ardelyx, Inc. 2014 Employee Stock Purchase Plan.    S-8    7/14/2014    99.6   
10.25#      Non-Employee Director Compensation Program.    S-1/A    6/9/2014    10.21   
23.1      Consent of Independent Registered Public Accounting Firm             X

 

5


           

Incorporated by Reference

Exhibit
Number

    

Exhibit Description

  

Form

  

Date

  

Number

  

Filed
Herewith

31.1      Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.             X
31.2      Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.             X
32.1*      Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C §1350.            
101.INS*      XBRL Instance Document            
101.SCH*      XBRL Taxonomy Extension Schema Document            
101.CAL*      XBRL Taxonomy Extension Calculation Linkbase Document            
101.DEF*      XBRL Taxonomy Extension Definition Linkbase Document            
101.LAB*      XBRL Taxonomy Extension Label Linkbase Document            
101.PRE*      XBRL Taxonomy Extension Presentation Linkbase Document            

 

Confidential treatment granted as to portions of this Exhibit. The confidential portions of this Exhibit have been omitted and are marked by asterisks.
# Indicates management contract or compensatory plan.
* Previously filed with our Annual Report on Form 10-K filed with the Commission on March 5, 2015.

 

6

EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-197408) pertaining to the 2008 Stock Incentive Plan, as amended, the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan of Ardelyx, Inc., of our report dated March 5, 2015, with respect to the financial statements of Ardelyx, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2014.

/s/ Ernst & Young LLP

Redwood City, California

March 5, 2015

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Michael Raab, certify that:

 

1. I have reviewed this Amendment No. 1 to the annual report on Form 10-K of Ardelyx, Inc.; and

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: March 11, 2015

By:

/s/ Michael Raab

Michael Raab

President, Chief Executive Officer and Director

(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Mark Kaufmann, certify that:

 

1. I have reviewed this Amendment No. 1 to the annual report on Form 10-K of Ardelyx, Inc.; and

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: March 11, 2015

By:

/s/ Mark Kaufmann

Mark Kaufmann

Chief Financial Officer

(Principal Financial Officer)